FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination with chemotherapy.
The Gut Microbiome Offers Clues to Immunotherapy Efficacy in Advanced Gastric Cancer
Japanese researchers found a link between the gut microbiome and a positive response to the immunotherapy drug Opdivo in patients with gastric... Read More
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Immunotherapy for stomach cancer may work better if the therapy is delivered earlier in the course of disease and in combination with... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer slowed down... Read More
Immune Protein IL-17A Responsible for Lethal Side Effects of Gastric Cancer
Researchers in Japan discovered that the pro-inflammatory cytokine IL-17A plays a role in promoting peritoneal spread in gastric cancer, and they suggested... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
First-Line Pembrolizumab and Trastuzumab in HER2-Positive Esophageal, Gastric, or Gastroesophageal Junction Cancer
Patients with Her2-positive gastric cancer taking a combination of the immune-boosting drug Keytruda with Herceptin had progression-free survival rate at six months... Read More
Gritstone posts ‘one of the most potent immunogenic-responses for a neoantigen vaccine’
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.
Pfizer, Merck KGaA’s Bavencio flunks study in hard-to-treat gastric cancer
The PD-L1 inhibitor Bavencio did not outperform chemo at extending patients’ lives in a major study in gastric cancer, raising questions about... Read More